Inicio・Lista de Acciones・DexCom Inc

DexCom Inc

Cerrado

SectorSanidad

86.95 -0.29

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

85.87

Máximo

87.73

Métricas clave
By Trading Economics
Ingresos	50M 249M
Ventas	117M 1.3B
P/B Media del Sector	34.51 68.51
BPA	0.7
Margen de beneficios	19.039
Empleados	11,000
EBITDA	52M 389M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+3.68% upside

Dividendos
By Acuity
Próximas Ganancias	29 oct 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	4.6B 33B
Apertura anterior	87.24
Cierre anterior	86.95

Noticias sobre sentimiento de mercado

By Acuity

21%

79%

64 / 340 Clasificación en Healthcare

DexCom Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 ago 2026, 19:56 UTC

Dexcom Inc. shares are lower today, pulling back after reaching a session high. The broader market benefits from a significant decline in crude oil prices.

3 ago 2026, 20:02 UTC

News

Social Media

Dexcom Inc. shares are higher following strong Q2 results and raised revenue guidance to $5.22 billion. Canaccord increased its price target to $90.

31 jul 2026, 20:04 UTC

News

Social Media

Dexcom Inc. shares are higher following analyst upgrades and strong earnings, with second-quarter revenue of $1.31 billion exceeding expectations and guidance raised to $5.22 billion.

30 jul 2026, 23:51 UTC

News

Social Media

Dexcom reported second-quarter revenue of $1.308 billion and adjusted EPS of $0.70, raising its fiscal year 2026 revenue guidance, with shares trading higher in after-market hours.

29 jul 2026, 23:41 UTC

Dexcom Inc is trading higher in after-market hours, supported by overall market strength. The asset remains above its 20-day moving average.

28 jul 2026, 20:06 UTC

News

Dexcom shares rise after UBS initiated coverage with a Buy rating. The stock is advancing since Monday's close of $73.37 amid positive sentiment in the Health Care Equipment sector.

27 jul 2026, 19:06 UTC

News

Dexcom Inc. gains Health Canada approval for its Dexcom G7 continuous glucose monitoring system, boosting marketability and user adoption amid positive analyst sentiment.

24 jul 2026, 15:22 UTC

Dexcom Inc's shares are higher today, driven by gains in the Health Care Equipment sub-sector. No specific company news was identified for the movement.

22 jul 2026, 20:01 UTC

Dexcom Inc. shares are lower today, continuing a decline since Tuesday. Earlier, the stock briefly rose before pulling back.

21 jul 2026, 19:26 UTC

Dexcom Inc is trading lower, continuing a trend of three consecutive declines. The stock reached a session low earlier today before a slight recovery.

20 jul 2026, 19:22 UTC

Dexcom Inc shares are lower amid broader market declines and rising Treasury yields. The stock remains near the upper end of its one-month trading range.

Comparación entre iguales

Cambio de precio

DexCom Inc previsión

Precio Objetivo

By TipRanks

3.68% repunte

Estimación a 12 Meses

Media 90.52 USD 3.68%

Máximo 112 USD

Mínimo 64 USD

De acuerdo con 23 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para DexCom Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

23 ratings

Comprar

Mantener

Vender

De acuerdo con 23 analistas que ofrecen calificaciones bursátiles a para DexCom Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

64 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.